We’re a global biotech company empowering next-gen drug discovery, from target ID to IND application. With our cutting-edge RenMice® platforms and proprietary gene-editing technology, we support partners worldwide in developing fully human antibodies. Our team also provides humanized models, preclinical pharmacology, and custom gene-editing services to accelerate innovation in the biomedical community.